Clinico-Pathologic Profile and Treatment Outcomes of Patients with Diffuse Large B Cell Lymphoma Based on Cell of Origin Classification
- Resource Type
- Authors
- Sajini Elizabeth Jacob; Yadav Nisha; Biswajit Dubashi; Prasanth Ganesan; Divya Bala Thumaty; Sohan Singh Mandloi; Smita Kayal; Debdatta Basu
- Source
- Indian J Hematol Blood Transfus
- Subject
- medicine.medical_specialty
Hematology
business.industry
Cell of origin
030204 cardiovascular system & hematology
medicine.disease
Gastroenterology
Subtyping
Lymphoma
03 medical and health sciences
0302 clinical medicine
medicine.anatomical_structure
hemic and lymphatic diseases
Internal medicine
medicine
Original Article
Rituximab
Stage (cooking)
business
Diffuse large B-cell lymphoma
B cell
030215 immunology
medicine.drug
- Language
- ISSN
- 0974-0449
0971-4502
Diffuse large B cell lymphoma (DLBCLs) constitute 40% of all non-Hodgkin lymphoma and it represent a heterogeneous group of neoplasms rather than a single clinicopathological entity. We analysed the outcomes and clinical features based on the cell of origin in a series of patients with DLBCL from our institute. Medical case records of all newly diagnosed DLBCL treated in our institute from January 2015 to July 2017 were analysed for this study. Cell of origin classification was based on immunohistochemistry using Hans algorithm. Kaplan–Meier curves were used to determine survival. Ninety-five patients were diagnosed to have DLBCL subtype. Immunophenotypic subtyping was available for 71 patients. The median age at diagnosis was 56 years with no difference between Germinal centre B cell (GCB) and non-Germinal centre B cell (non-GCB) subtypes. Approximately 44% of patients had extra-nodal disease, stomach being the commonest site. Forty percent of patients had stage III/IV disease. Bulky disease and extra-nodal presentation was predominantly seen with non-GCB subtype (46% vs 20% and 36% vs 29% respectively). Rituximab was used in 75% of the patients with DLBCL. The 2-year disease-free survival was 70% versus 53% (p = 0.38) in GCB versus non-GCB subtype. This is one of the few data on DLBCL patients reported from India which has described outcomes based on the cell of origin. The disease-free survival in our country appears to be superior in GCB subtype which needs to be confirmed in a larger subset of patients.